The oral potassium-competitive acid blocker vonoprazan was noninferior and superior to the proton pump inhibitor lansoprazole for erosive esophagitis in a phase 3 trial. Medscape Medical News
The oral potassium-competitive acid blocker vonoprazan was noninferior and superior to the proton pump inhibitor lansoprazole for erosive esophagitis in a phase 3 trial. Medscape Medical News